Aberdeen Group plc → ProQR Therapeutics NV PRQR

Stake: — Shares: — Class: Ordinary Shares, nominal value EUR0.04 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 28/100

Passive Schedule 13G filer baseline
1 independent officer/director Code-P buyer ($261,000 in ±30d)
Moderate short days-to-cover (3.0 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

1 buys · 0 sales · 0 awards/exercises

Issuer Cluster

5 13D/G filings on this issuer

4 other filings besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 3.02

2,909,335 shares short · +1.5% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-07-09	de Boer Daniel Anton	director, officer	Buy	150,000	$1.74	$261K

Other 13D/G Filings on ProQR Therapeutics NV

Filed	Form	Filer	Stake	Shares
2026-07-29	SCHEDULE 13D/A	VAN HERK INVESTMENTS B.V.	—	15,384,250	view →
2026-06-30	SCHEDULE 13D/A	VAN HERK INVESTMENTS B.V.	—	15,384,250	view →
2026-06-03	SCHEDULE 13D/A	VAN HERK INVESTMENTS B.V.	14.60%	15,384,250	view →
2025-09-30	SCHEDULE	VAN HERK INVESTMENTS B.V.	13.60%	14,329,690	view →

Other Filings by Aberdeen Group plc

Filed	Form	Issuer	Stake	Shares
2026-07-27	SCHEDULE 13G	Eloxx Pharmaceuticals Inc	—	—	view →
2026-07-20	SCHEDULE 13G/A	CODEXIS, INC.	—	—	view →
2026-07-20	SCHEDULE 13G/A	uniQure N.V.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →